{
  "id": "resp_0b26a3436312d22400693c7db06b50819485362086cf21e7e5",
  "object": "response",
  "created_at": 1765572016,
  "status": "completed",
  "background": false,
  "billing": {
    "payer": "developer"
  },
  "error": null,
  "incomplete_details": null,
  "instructions": null,
  "max_output_tokens": null,
  "max_tool_calls": null,
  "model": "gpt-5.2-2025-12-11",
  "output": [
    {
      "id": "rs_0b26a3436312d22400693c7db0d5a08194bbddbbaea63cf52c",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0b26a3436312d22400693c7db3b548819480a347b7920255e6",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "CDK12 CDK13 inhibitor WO patent triple negative breast cancer"
      }
    },
    {
      "id": "rs_0b26a3436312d22400693c7db64d188194beed4775704e96c1",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0b26a3436312d22400693c7dbb03f881949d9e785c174373b7",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "SR-4835 clinical trial NCT"
      }
    },
    {
      "id": "rs_0b26a3436312d22400693c7dbe12a081949bcd55a94cd80127",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0b26a3436312d22400693c7dc22a4c819490107fe4c0b7c248",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://patents.google.com/patent/WO2019217421A1/en"
      }
    },
    {
      "id": "rs_0b26a3436312d22400693c7dc338c881949c4dbe91ca7577aa",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0b26a3436312d22400693c7dc3833c81949f8a0538a42f9dd2",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "find_in_page",
        "pattern": "WO",
        "url": "https://patents.google.com/patent/MX2022008099A/en"
      }
    },
    {
      "id": "rs_0b26a3436312d22400693c7dc51068819483062f31fd11e440",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0b26a3436312d22400693c7dc690e48194a29ef42fec169469",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "find_in_page",
        "pattern": "triple negative",
        "url": "https://patents.google.com/patent/WO2019217421A1/en"
      }
    },
    {
      "id": "rs_0b26a3436312d22400693c7dc8b3548194bdafd0d7315607e6",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0b26a3436312d22400693c7dceba54819488c7797dfdcaaa41",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "ZLC491 WO patent"
      }
    },
    {
      "id": "rs_0b26a3436312d22400693c7dd0ffb88194a5146c64c4b38a21",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0b26a3436312d22400693c7dd231888194bca4921960cfd056",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://patents.google.com/patent/WO2021138215A1/en"
      }
    },
    {
      "id": "rs_0b26a3436312d22400693c7dd324c08194b6eb9b08ed4f8874",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "msg_0b26a3436312d22400693c7de910308194bcd869e64e5496ee",
      "type": "message",
      "status": "completed",
      "content": [
        {
          "type": "output_text",
          "annotations": [
            {
              "type": "url_citation",
              "end_index": 454,
              "start_index": 379,
              "title": "WO2019217421A1 - Small molecule inhibitors of cdk12/cdk13 \n        - Google Patents",
              "url": "https://patents.google.com/patent/WO2019217421A1/en"
            },
            {
              "type": "url_citation",
              "end_index": 942,
              "start_index": 867,
              "title": "WO2021138215A1 - Treatment of cancer with cdk12/13 inhibitors \n        - Google Patents",
              "url": "https://patents.google.com/patent/WO2021138215A1/en"
            },
            {
              "type": "url_citation",
              "end_index": 1350,
              "start_index": 1262,
              "title": "Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/31668947/?utm_source=openai"
            },
            {
              "type": "url_citation",
              "end_index": 1850,
              "start_index": 1762,
              "title": "Noncovalent CDK12/13 dual inhibitors-based PROTACs degrade CDK12-Cyclin K complex and induce synthetic lethality with PARP inhibitor - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/34864331/?utm_source=openai"
            },
            {
              "type": "url_citation",
              "end_index": 2278,
              "start_index": 2190,
              "title": "Discovery of ZLC491 as a Potent, Selective, and Orally Bioavailable CDK12/13 PROTAC Degrader - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/39388374/?utm_source=openai"
            },
            {
              "type": "url_citation",
              "end_index": 2705,
              "start_index": 2617,
              "title": "Discovery of a Highly Potent and Selective Dual PROTAC Degrader of CDK12 and CDK13 - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/35938508/?utm_source=openai"
            },
            {
              "type": "url_citation",
              "end_index": 3114,
              "start_index": 3026,
              "title": "Discovery of novel imidazo[1,2-b]pyridazine derivatives as potent covalent inhibitors of CDK12/13 - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/39955845/?utm_source=openai"
            },
            {
              "type": "url_citation",
              "end_index": 3568,
              "start_index": 3480,
              "title": "Discovery of a novel dual-target inhibitor of CDK12 and PARP1 that induces synthetic lethality for treatment of triple-negative breast cancer - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/37478560/?utm_source=openai"
            },
            {
              "type": "url_citation",
              "end_index": 3949,
              "start_index": 3861,
              "title": "Rational Design of CDK12/13 and BRD4 Molecular Glue Degraders - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/40626960/?utm_source=openai"
            }
          ],
          "logprobs": [],
          "text": "- **WO2019217421A1 - Small molecule inhibitors of cdk12/cdk13 - Google Patents**  \n  URL: `https://patents.google.com/patent/WO2019217421A1/en`  \n  Quote snippets:\n  - “Publication number **WO2019217421A1**”  \n  - “CDK12 mutations have been reported… including **triple negative breast cancer**…”  \n  - “the only selective inhibitor of **CDK12/13** reported so far - **THZ531**” ([patents.google.com](https://patents.google.com/patent/WO2019217421A1/en))\n\n- **WO2021138215A1 - Treatment of cancer with cdk12/13 inhibitors - Google Patents**  \n  URL: `https://patents.google.com/patent/WO2021138215A1/en`  \n  Quote snippets:\n  - “Publication number **WO2021138215A1**”  \n  - “method of treating a **triple-negative breast cancer**… administering… a compound of **Formula (I)**”  \n  - “**FIGS. 3A and 3B** depict dose-response curves for **THZ531** and **compound 1**” ([patents.google.com](https://patents.google.com/patent/WO2021138215A1/en))\n\n- **Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer - PubMed**  \n  URL: `https://pubmed.ncbi.nlm.nih.gov/31668947/`  \n  Quote snippets:\n  - “development of **SR-4835**, a highly selective dual inhibitor of **CDK12** and **CDK13**”  \n  - “disables triple-negative breast cancer (**TNBC**) cells.” ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/31668947/?utm_source=openai))\n\n- **Noncovalent CDK12/13 dual inhibitors-based PROTACs degrade CDK12-Cyclin K complex and induce synthetic lethality with PARP inhibitor - PubMed**  \n  URL: `https://pubmed.ncbi.nlm.nih.gov/34864331/`  \n  Quote snippets:\n  - “a potent **PROTAC** degrader **PP-C8** based on the noncovalent dual inhibitors of **CDK12/13**”  \n  - “**PP-C8**… demonstrates… effects… in triple-negative breast cancer (**TNBC**).” ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/34864331/?utm_source=openai))\n\n- **Discovery of ZLC491 as a Potent, Selective, and Orally Bioavailable CDK12/13 PROTAC Degrader - PubMed**  \n  URL: `https://pubmed.ncbi.nlm.nih.gov/39388374/`  \n  Quote snippets:\n  - “discovery of **ZLC491** as a… orally bioavailable **CDK12/13 PROTAC degrader**”  \n  - “degraded **CDK12** and **CDK13**… in TNBC **MDA-MB-231** cells.” ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/39388374/?utm_source=openai))\n\n- **Discovery of a Highly Potent and Selective Dual PROTAC Degrader of CDK12 and CDK13 - PubMed**  \n  URL: `https://pubmed.ncbi.nlm.nih.gov/35938508/`  \n  Quote snippets:\n  - “dual **CDK12/13** degraders… (**PROTAC**) technology.”  \n  - “optimal compound **7f**… degraded **CDK12** and **CDK13**… in **MDA-MB-231** breast cancer cells.” ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/35938508/?utm_source=openai))\n\n- **Discovery of novel imidazo[1,2-b]pyridazine derivatives as potent covalent inhibitors of CDK12/13 - PubMed**  \n  URL: `https://pubmed.ncbi.nlm.nih.gov/39955845/`  \n  Quote snippets:\n  - “compound **24**… with **CDK12 IC_{50}** of 15.5 nM and **CDK13 IC_{50}** of 12.2 nM.”  \n  - “superior efficacy to… **THZ531**.” ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/39955845/?utm_source=openai))\n\n- **Discovery of a novel dual-target inhibitor of CDK12 and PARP1 that induces synthetic lethality for treatment of triple-negative breast cancer - PubMed**  \n  URL: `https://pubmed.ncbi.nlm.nih.gov/37478560/`  \n  Quote snippets:\n  - “dual-target inhibitor (**12e**)… against **CDK12**… and **PARP1**”  \n  - “treatment of triple-negative breast cancer (**TNBC**)” ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/37478560/?utm_source=openai))\n\n- **Rational Design of CDK12/13 and BRD4 Molecular Glue Degraders - PubMed**  \n  URL: `https://pubmed.ncbi.nlm.nih.gov/40626960/`  \n  Quote snippets:\n  - “**CDK12/13**… **molecular glue degraders**”  \n  - “enabled the recruitment of… **DDB1**… into a… **CDK12/13 molecular glue degrader**.” ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/40626960/?utm_source=openai))"
        }
      ],
      "role": "assistant"
    }
  ],
  "parallel_tool_calls": true,
  "previous_response_id": null,
  "prompt_cache_key": null,
  "prompt_cache_retention": null,
  "reasoning": {
    "effort": "medium",
    "summary": null
  },
  "safety_identifier": null,
  "service_tier": "default",
  "store": true,
  "temperature": 1.0,
  "text": {
    "format": {
      "type": "text"
    },
    "verbosity": "medium"
  },
  "tool_choice": "auto",
  "tools": [
    {
      "type": "web_search",
      "filters": null,
      "search_context_size": "medium",
      "user_location": {
        "type": "approximate",
        "city": null,
        "country": "US",
        "region": null,
        "timezone": null
      }
    }
  ],
  "top_logprobs": 0,
  "top_p": 0.98,
  "truncation": "disabled",
  "usage": {
    "input_tokens": 33561,
    "input_tokens_details": {
      "cached_tokens": 4352
    },
    "output_tokens": 4392,
    "output_tokens_details": {
      "reasoning_tokens": 3227
    },
    "total_tokens": 37953
  },
  "user": null,
  "metadata": {}
}